首页|DOMINANT LETHAL AND HERITABLE TRANSLOCATION TESTS WITH CHLORAMBUCIL AND MELPHALAN IN MALE MICE
DOMINANT LETHAL AND HERITABLE TRANSLOCATION TESTS WITH CHLORAMBUCIL AND MELPHALAN IN MALE MICE
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Chemicals used in the treatment of cancer include several that are potent mutagens in a range of in vitro and in vivo assays. For some, genetic effects have also been demonstrated in humans, detected as chromosomal aberrations in peripheral lymphocytes. Because (1) many of these agents are confirmed mutagens, (2) humans are exposed to them in relatively high doses, and (3) an increasing number of early cancer victims are surviving to reproductive age, it is important that information be available on the genetic and reproductive hazards associated with exposure to these agents. Chlorambucil and melphalan are structurally related chemicals that are included in our efforts to identify and assess such hazards among cancer chemotherapy agents. To date, both have been reported to induce specific locus mutations in germ cells of male mice (Russell et al., 1989; Russell et al., 1992b) and melphalan is one of very few chemicals shown to induce such mutations in spermatogonial stem cells. More recently, both chemicals were found to have strong reproductive effects in female mice (Bishop and Generoso, 1995, in preparation). In the present studies, these chemicals were tested for the induction of dominant lethal mutations and heritable translocations in male mice. Both chemicals were found to have reproductive effects attributable to cytotoxicity in specific male germ cell stages and to induce dominant lethal mutations and heritable translocations in postmeiotic germ cells, particularly in mid to early stage spermatids. Thus, relatively extensive data are now available for assessing the genetic and reproductive hazards that may result from therapeutic exposures to these chemicals.
Chemotherapeutic agentChromosome damageGerm cellSpermMouse bone marrowBreast cancerMultiple myelomaCytogeneticabnormalitiesOvarian carcinomaAcute leukemiaChemotherapyTherapyRearrangementsMutations
NSTL
